MSD Receives European Approval Of Its Atypical Antipsychotic Medication SYCREST(R) For The Treatment Of Manic Episodes In Bipolar I Disorder

MSD (MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A). announced today that the European Commission has approved the Marketing Authorization Application (MAA) for SYCREST® (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults...

Read the original post at Psychology / Psychiatry News From Medical News Today ...

Share your thoughts.